12,282 Shares in Koninklijke Philips N.V. $PHG Acquired by West Family Investments Inc.

West Family Investments Inc. acquired a new stake in Koninklijke Philips N.V. (NYSE:PHG) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 12,282 shares of the technology company’s stock, valued at approximately $295,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AlphaCore Capital LLC purchased a new stake in shares of Koninklijke Philips during the second quarter worth $41,000. Whipplewood Advisors LLC boosted its position in Koninklijke Philips by 39.1% during the second quarter. Whipplewood Advisors LLC now owns 2,108 shares of the technology company’s stock worth $51,000 after acquiring an additional 592 shares during the last quarter. MAI Capital Management boosted its position in Koninklijke Philips by 167.7% during the second quarter. MAI Capital Management now owns 2,380 shares of the technology company’s stock worth $57,000 after acquiring an additional 1,491 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Koninklijke Philips by 1,170.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,439 shares of the technology company’s stock valued at $62,000 after acquiring an additional 2,247 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in Koninklijke Philips by 30.0% in the 2nd quarter. Blue Trust Inc. now owns 4,408 shares of the technology company’s stock valued at $106,000 after acquiring an additional 1,017 shares during the last quarter. Hedge funds and other institutional investors own 13.67% of the company’s stock.

Koninklijke Philips Stock Performance

Koninklijke Philips stock opened at $28.16 on Monday. The firm has a 50 day simple moving average of $27.90 and a 200-day simple moving average of $26.24. The stock has a market cap of $27.12 billion, a price-to-earnings ratio of 140.81, a price-to-earnings-growth ratio of 0.76 and a beta of 0.79. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.32 and a quick ratio of 0.86. Koninklijke Philips N.V. has a 1-year low of $21.48 and a 1-year high of $29.54.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings data on Tuesday, November 4th. The technology company reported $0.37 EPS for the quarter, meeting analysts’ consensus estimates of $0.37. The firm had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $4.30 billion. Koninklijke Philips had a return on equity of 12.14% and a net margin of 1.07%. On average, analysts expect that Koninklijke Philips N.V. will post 1.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on PHG shares. Wall Street Zen upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Koninklijke Philips in a research report on Tuesday, November 25th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Koninklijke Philips currently has a consensus rating of “Buy”.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.